Giuseppe Uccello: The Potential Cardioprotective Effect of Dapagliflozin in Patients with Breast Cancer
Giuseppe Uccello, Cardiologist at Alessandro Manzoni Hospital, shared a post on LinkedIn:
“In the Cardiology and Oncology divisions of our hospital, the randomized PROTECT trial has been ongoing for several months, in collaboration with “Policlinico San Matteo” of Pavia, to assess the potential cardioprotective effect of Dapagliflozin in patients with breast cancer undergoing anthracycline therapy.
The road toward preventing chemotherapy-induced cardiotoxicity is still a long one, but we hope to contribute by providing an additional tool.”
Title: SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial
Authors: A. Greco, V. Quagliariello, G. Rizzo, A. Tedeschi, S. Schirinzi, A. Turco, M. Galiazzo, M. Acquaro, M. De Amicis, C. Klersy, S. Ghio, L. Perrone, A. Paccone, G. Uccello, M. L. Canale, S. Oliva, F. Guerra, L. De Luca, N. Maurea and L. Scelsi
Read The Full Article at Cardio-Oncology.
More Posts Featuring Breast Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023